الفهرس 
Review of LiteratureOnly 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
Long non-coding RNA (CCAT-1) and micro RNA (miRNA-155a) are in a tight relation with different types of cancers as well as in AML. However, the prognostic value of CCAT-1/miR-155a pathway in AML has not been investigated. The purpose of this study is to investigate the correlation of CCAT-1 expression with clinic-pathological features and the clinical prognosis of the AML patients. Also to find out the association between CCAT-1 expression and expression of miRNA-155a as a targeting gene for CCAT-1 and to improve understanding of the roles and the clinic implications of CCAT-1 in the development and progression of AML.
This current study was conducted at (Internal Medicine Hospitals, Ain Shams University, Department of Hematology). It was performed on 70 individuals categorized as 50 AML patients and 20 healthy control groups. Peripheral blood samples were collected for molecular analysis of miR-155a, Lnc-CCAT-1 extraction and expression using Real time PCR by SYBR green kit.
In AML group, miR-155 expression was highly significant in clinical response with (P≤ 0.004) and was slightly significant in cytogenetic abnormality, BM blasts; MRD with (P≤ 0.05, P≤0.03, P≤0.02)
respectively compared to the control group. On the other hand, the rest of parameters as age subgroups, gender, AML phenotype, TLC, hemoglobin, platelet count were non-significant compared with control group.
As well as, the miR-155 was as oncogene and its expression increased by 5.6 folds compared to healthy control group [P≤0.001] and a higher diagnostic and prognostic efficiency in the discriminating between both high risk AML groups and healthy control. It was reported that miR-155a shown highly significance with (P≤0.001 and 0.004) respectively, in the parameter AML/control and clinical response and a moderate significant (P≤0.02) in MRD and non-significant in in TLC and platelet count.
It was shown that, expression of Lnc-CCAT-1 in AML group was highly significance in TLC, platelet count, BM blasts , MRD as well as clinical response with (P≤0.001) compared with its expression in the control group. On the other side, non-significant expression of Lnc- CCAT-1 for other parameters under investigations in AML group as age subgroups, gender, AML phenotype, hemoglobin compared with control group.
Our results of this study concluded that, the Lnc-CCAT-1 works as an oncogene in case of AML patients and it’s expression was increased by 3.0
folds compared to healthy control group with high significance [P≤0.008]. It shows also a higher diagnostic and prognostic efficiency in the discrimination between both low and high-risk AML groups. Moreover, it represents a high significant difference (p≤0.001) in MRD, clinical response, BM blasts, TLC, platelet count with 95% confidence interval in AML/control comparison.